Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia

POLAT, Zülfikar; BAĞCI, Sait; KANTARCIOĞLU, Murat; ERÇİN, Cemal Nuri; Uygun, Ahmet; KİLCİLER, Güldem; TOROS, AHMET BURAK

Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia

Cemal Nuri ERÇİN, (GATA Gastroenteroloji Anabilim Dalı, Ankara, Türkiye)

Ahmet UYGUN, (GATA Gastroenteroloji Anabilim Dalı, Ankara, Türkiye)

Ahmet Burak TOROS, (GATA Gastroenteroloji Anabilim Dalı, Ankara, Türkiye)

Murat KANTARCIOĞLU, (GATA Gastroenteroloji Anabilim Dalı, Ankara, Türkiye)

Güldem KİLCİLER, (GATA Gastroenteroloji Anabilim Dalı, Ankara, Türkiye)

Zülfikar POLAT, (GATA Gastroenteroloji Anabilim Dalı, Ankara, Türkiye)

Sait BAĞCI (GATA Gastroenteroloji Anabilim Dalı, Ankara, Türkiye)

Turkish Journal of Gastroenterology

3 0

Yıl: 2010 Cilt: 21 Sayı: 1 Sayfa Aralığı: 12 - 16 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia

Öz:

Birinci basamak Helikobakter pilori eradikasyon tedavisinde en sık kullanılan antibiyotikler olan klaritromisin ve metranidazole direncin artması nedeniyle, yeni tedavi alternatiflerine ihtiyaç duyulmaktadır. Bu çalışmanın amacı; birinci basamak eradikasyon tedavisinde lansoprazol, levofloksasin ve amoksisilin'den oluşan üçlü tedavi protokolünün 7 ve 14 günlük etkinliğinin karşılaştırılmasıdır. Yöntem: Histoloji ve hızlı üreaz testi ile Helikobakter pilori varlığı gösterilmiş nonülser dispepsili 91 hasta çalışmaya alındı. Hastalar 7 günlük (Grup 1: 51 hasta) ve 14 günlük (Grup 2: 40 hasta) lansoprazol 30 mg (2x1), levofloksasin 500 mg (1x1) ve amoksisilin 1000 mg (2x1) tedavisi alacak şekilde randomize edildi ve 6 hafta süre ile izlendi. Eradikasyon, tedavi bitiminden 4 hafta sonra üre nefes testi ile değerlendirildi. Bulgular: Grup 1 hastalarının 41'i çalı şmayı tamamladı ve eradikasyon oranı %34.15 idi. Grup 2'de ise 38 hasta çalışmayı tamamladı ve eradikasyon oranı %72.22 idi. 7 ve 14 günlük tedaviler arasında eradikasyon oranı açısından anlamlı bir fark tespit edildi (p= 0.001). Sonuç: Ondört gün süreyle uygulanan lansoprazol, levofloksasin ve amoksisilinden oluşan üçlü protokol, Helikobakter pilori eradikasyonunda etkilidir, ancak 7 günlük tedavide eradikasyon oranı çok düşüktür ve kullanılmamalıdır.

Anahtar Kelime: Anti-bakteriyel ajanlar Helicobacter enfeksiyonları Ofloksazin Nefes testleri Dispepsi 2-Piridinmetilsülfinilbenzimidazol Helicobacter pylori İlaç tedavisi, kombinasyon Anti-enfektif ajanlar Amoksisilin

Konular: Cerrahi

Helikobakter pilori pozitif nonülser dispepsili hastalarda birinci basamak tedavide levofloksasin içeren üçlü tedavinin 7 ve 14 günlük etkinliğinin karşılaştırılması

Öz:

Because of the increasing resistance to clarithromycin and metronidazole, the most frequently used antibiotics in the first-line therapy of Helicobacter pylori eradication, new therapeutic alternatives are needed. The aim of this study was to compare the efficacy of 7- and 14-day triple therapy including lansoprazole, levofloxacin and amoxicillin for Helicobacter pylori eradication as a first-line therapy. Methods: Ninety-one non-ulcer dyspeptic patients infected with Helicobacter pylori as diagnosed by both histology and a rapid urease test were included in this study. Patients were randomized to receive either 7- (Group 1; 51 patients) or 14-day (Group 2; 40 patients) therapy with lansoprazole (30 mg b.i.d.), plus levofloxacin (500 mg o.i.d.) and amoxicillin (1000 mg b.i.d.) and they were followed for six weeks. Eradication was assessed by 14C-urea breath test four weeks after completing the treatment protocols. Results: In Group 1, 41 patients completed the treatment and the eradication rate was 34.15%. In group 2, 36 patients completed the treatment and the eradication rate was 72.2% (p= 0.001 vs group 1). Conclusions: Triple therapy with lansoprazole, levofloxacin and amoxicillin for 14 days was effective for Helicobacter pylori eradication, but 7-day therapy with the same protocol had a lower and unacceptable cure rate and should not be used.

Anahtar Kelime: Dyspepsia 2-Pyridinylmethylsulfinylbenzimidazoles Helicobacter pylori Drug Therapy, Combination Anti-Infective Agents Amoxicillin Anti-Bacterial Agents Helicobacter Infections Ofloxacin Breath Tests

Konular: Cerrahi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-81.
2. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998; 13: 1-12.
3. Bourke B, Ceponis P, Chiba N, et al. Canadian Helicobacter Study Group Consensus Conference: Update on the approach to Helicobacter pylori infection in children and adolescents-- an evidence-based evaluation. Can J Gastroenterol 2005; 19: 399-408.
4. Malfertheiner P, Bayerdörffer E, Diete U, et al. The GUMACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther 1999; 13: 703-12.
5. Zanten SJ, Bradette M, Farley A, et al. The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment Pharmacol Ther 1999; 13: 289-95.
6. Gisbert JP, Khorrami S, Calvet X, Pajares JM. Pantoprazole based therapies in Helicobacter pylori eradication: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2004; 16: 89-99.
7. Baños F, Madridejos R, Cabezas C, et al. Effectiveness of omeprazole, clarithromycin and amoxycillin therapy to eradicate Helicobacter pylori in patients with active peptic ulcer. Preliminary results of GENPY study. Med Clin (Barc) 2000; 114: 441-3.
8. Palmas F, Pellicano R, Massimetti E, et al. Eradication of Helicobacter pylori infection with proton pump inhibitorbased triple therapy. A randomised study. Panminerva Med 2002; 44: 145-7.
9. Ayd'n A, Faik G, Onder F, et al. The effectiveness of ranitidine bismuth citrate-amoxicillin-clarithromycin combination in eradication of HP in clarithromycin-resistant and - sensitive cases [Abstract]. Turk J Gastroenterol 2004 (Suppl): 57.
10. Kadayifci A, Buyukhatipoglu H, Cemil Savas M, Simsek I. Eradication of Helicobacter pylori with triple therapy: an epidemiologic analysis of trends in Turkey over 10 years. Clin Ther 2006; 28: 1960-6.
11. Bock H, Koop H, Lehn N, Heep M. Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience. J Clin Gastroenterol 2000; 31: 222-5.
12. Perri F, Festa V, Clemente R, et al. Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000; 14: 311-6.
13. Canducci F, Ojetti V, Pola P, et al. Rifabutin-based Helicobacter pylori eradication 'rescue therapy'. Aliment Pharmacol Ther 2001; 15: 143.
14. Schito AM, Schito GC. Levofloxacin, a broad spectrum anti- infective: from Streptococcus pneumoniae to Pseudomonas aeruginosa. J Chemother 2004; 16: 3-7.
15. Candelli M, Nista EC, Carloni E, et al. Treatment of H. pylori infection: a review. Curr Med Chem 2005; 12: 375-84.
16. Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs 2003; 63: 2769-802.
17. Antos D, Schneider-Brachert W, Bästlein E, et al. 7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity. Helicobacter 2006; 11: 39-45.
18. Cammarota G, Cianci R, Cannizzaro O, et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 1339-43.
19. Di Caro S, Zocco MA, Cremonini F, et al. Levofloxacin based regimens for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 2002; 14: 1309-12.
20. Marzio L, Coraggio D, Capodicasa S, et al. Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole. Helicobacter 2006; 11: 237-42.
21. Gisbert JP, Fernández-Bermejo M, Molina-Infante J, et al. First-line triple therapy with levofloxacin for Helicobacter pylori eradication. Aliment Pharmacol Ther 2007; 26: 495-500.
22. Nista EC, Candelli M, Zocco MA, et al. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol 2006; 101: 1985-90.
23. Schrauwen RW, Janssen MJ, de Boer WA. Seven-day PPItriple therapy with levofloxacin is very effective for Helicobacter pylori eradication. Neth J Med 2009; 67: 96-101.
24. Sánchez JE, Sáenz NG, Rincón MR, et al. Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/ dalfopristin and new quinolones. J Antimicrob Chemother 2000; 46: 283-5.
25. Tanaka M, Isogai E, Isogai H, et al. Synergic effect of quinolone antibacterial agents and proton pump inhibitors on Helicobacter pylori. J Antimicrob Chemother 2002; 49: 1039-40.
26. Just PM. Overview of the fluoroquinolone antibiotics. Pharmacotherapy 1993; 13: 4S-17S.
27. Sprandel KA, Rodvold KA. Safety and tolerability of fluoroquinolones. Clin Cornerstone 2003; Suppl 3: S29-36.
28. Edlund C, Nord CE. Effect of quinolones on intestinal ecology. Drugs 1999; Suppl 2: 65-70.
29. Nightingale CH. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. Pharmacotherapy 2000; 20: 245-56.
30. Watanabe Y, Aoyama N, Shirasaka D, et al. Levofloxacin based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication with standard triple therapy. Dig Liver Dis 2003; 35: 711-5.
31. Gatta L, Zullo A, Perna F, et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther 2005; 22: 45-9.
32. Bilardi C, Dulbecco P, Zentilin P, et al. A 10-day levofloxacin- based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. Clin Gastroenterol Hepatol 2004; 2: 997-1002.
33. Matsumoto Y, Miki I, Aoyama N, et al. Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan. Dig Liver Dis 2005; 37: 821-5.
34. Gisbert JP, Bermejo F, Castro-Fernández M, et al. Secondline rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am J Gastroenterol 2008; 103: 71-6.
35. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacinbased triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a metaanalysis. Am J Gastroenterol 2006; 101: 488-96.
36. Dumlu GS, Karakan T, Degertekin B, et al. Efficacy of 14 days levofloxacin based triple therapy for Helicobacter pylori infection. Endoskopi 2004; 15: 54-9.
37. Carothers JJ, Bruce MG, Hennessy TW, et al. The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection. Clin Infect Dis 2007; 44: e5-8.
38. Cattoir V, Nectoux J, Lascols C, et al. Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility. Int J Antimicrob Agents 2007; 29: 389-96.
39. Perna F, Zullo A, Ricci C, et al. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig Liver Dis 2007; 39: 1001-5.
40. Mégraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 17: 1333-43.
41. Graham DY, Abudayyeh S, El-Zimaity HM, et al. Sequential therapy using high-dose esomeprazole-amoxicillin followed by gatifloxacin for Helicobacter pylori infection. Aliment Pharmacol Ther 2006; 24: 845-50.

APA	ERÇİN C, Uygun A, TOROS A, KANTARCIOĞLU M, KİLCİLER G, POLAT Z, BAĞCI S (2010). Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia. , 12 - 16.
Chicago	ERÇİN Cemal Nuri,Uygun Ahmet,TOROS AHMET BURAK,KANTARCIOĞLU Murat,KİLCİLER Güldem,POLAT Zülfikar,BAĞCI Sait Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia. (2010): 12 - 16.
MLA	ERÇİN Cemal Nuri,Uygun Ahmet,TOROS AHMET BURAK,KANTARCIOĞLU Murat,KİLCİLER Güldem,POLAT Zülfikar,BAĞCI Sait Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia. , 2010, ss.12 - 16.
AMA	ERÇİN C,Uygun A,TOROS A,KANTARCIOĞLU M,KİLCİLER G,POLAT Z,BAĞCI S Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia. . 2010; 12 - 16.
Vancouver	ERÇİN C,Uygun A,TOROS A,KANTARCIOĞLU M,KİLCİLER G,POLAT Z,BAĞCI S Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia. . 2010; 12 - 16.
IEEE	ERÇİN C,Uygun A,TOROS A,KANTARCIOĞLU M,KİLCİLER G,POLAT Z,BAĞCI S "Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia." , ss.12 - 16, 2010.
ISNAD	ERÇİN, Cemal Nuri vd. "Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia". (2010), 12-16.

APA	ERÇİN C, Uygun A, TOROS A, KANTARCIOĞLU M, KİLCİLER G, POLAT Z, BAĞCI S (2010). Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia. Turkish Journal of Gastroenterology, 21(1), 12 - 16.
Chicago	ERÇİN Cemal Nuri,Uygun Ahmet,TOROS AHMET BURAK,KANTARCIOĞLU Murat,KİLCİLER Güldem,POLAT Zülfikar,BAĞCI Sait Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia. Turkish Journal of Gastroenterology 21, no.1 (2010): 12 - 16.
MLA	ERÇİN Cemal Nuri,Uygun Ahmet,TOROS AHMET BURAK,KANTARCIOĞLU Murat,KİLCİLER Güldem,POLAT Zülfikar,BAĞCI Sait Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia. Turkish Journal of Gastroenterology, vol.21, no.1, 2010, ss.12 - 16.
AMA	ERÇİN C,Uygun A,TOROS A,KANTARCIOĞLU M,KİLCİLER G,POLAT Z,BAĞCI S Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia. Turkish Journal of Gastroenterology. 2010; 21(1): 12 - 16.
Vancouver	ERÇİN C,Uygun A,TOROS A,KANTARCIOĞLU M,KİLCİLER G,POLAT Z,BAĞCI S Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia. Turkish Journal of Gastroenterology. 2010; 21(1): 12 - 16.
IEEE	ERÇİN C,Uygun A,TOROS A,KANTARCIOĞLU M,KİLCİLER G,POLAT Z,BAĞCI S "Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia." Turkish Journal of Gastroenterology, 21, ss.12 - 16, 2010.
ISNAD	ERÇİN, Cemal Nuri vd. "Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia". Turkish Journal of Gastroenterology 21/1 (2010), 12-16.